Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.53 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.43 |
| ▸ | ITGAL | P20701 | 2/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4347089 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL1246595 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL757072 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL6852847 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL6136566 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL7148009 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL7258586 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL150536 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL31182997 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL18075525 | 0.96 | ECE1 (0.56) | ECE1ITGB2ICAM1ITGALPDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116034163-A | Humic substances for producing erythritol | 康齐尔庄园有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-114667347-A | Process for producing ethanol | 帝斯曼知识产权资产管理有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-110423705-A | For the method by product yield and yield in addition alternately electron acceptor improvement microorganism | LALLEMAND HUNGARY LIQUIDITY MAN LLC | 2019-11-08 | — | — | CN | disclosed |
| CN-109790551-A | Improved gene editing | 奥斯陆大学医院HF | 2019-05-21 | — | — | CN | disclosed |
| CN-107189954-A | By acetic acid and the engineered yeast bacterial strain of glycerol production ethanol | 帝斯曼知识产权资产管理有限公司 | 2017-09-22 | — | — | CN | disclosed |
| CN-103491979-B | Malaria vaccine based on pre-erythrocytic antigens from Plasmodium falciparum | 马尔瓦有限责任公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-101321778-A | Plasmodium liver stage antigens | SEATTLE BIOMEDICAL RES INST (US) | 2008-12-10 | — | — | CN | disclosed |
| CN-100340291-C | F1t4(VEGFR-3) as target for tumor imaging and anti-tumor therapy | LUDWIG INST CANCER RES (US) | 2007-10-03 | — | — | CN | disclosed |
| CN-1494552-A | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy | ·��ά��֢�о�Ժ | 2004-05-05 | — | — | CN | disclosed |
| CN-1329504-A | F1t4 (VEGFR-3) as target for tumor imaging and anti-tumor therapy | LUDWIG INST CANCER RES (US) | 2002-01-02 | — | — | CN | disclosed |
| WO-1991008756-A1 | NOVEL MALARIAL SPOROZOITE PEPTIDE ANTIGENS | BIOMEDICAL RESEARCH INSTITUTE (US) | 1991-06-27 | — | — | WO | disclosed |